Otava, Ltd - synthetic organic compounds for research and drug discovery
Otava, Ltd - synthetic organic compounds for research and drug discovery
Natural Product-Like Library
Natural Product-Like LibraryNatural Product-Like Library has been designed as a special screening library containing synthetic compounds similar to natural products.
Read more...
 
SuFEx Handle Fragment Library

SuFEx Handle Fragment Library

SuFEx (Sulfur-Fluoride Exchange) Chemistry represents the next-generation approach to covalent drug discovery, chemical biology, and synthetic chemistry. Building on the principles of click chemistry, SuFEx reactions leverage the unique S(VI)–F bond, allowing precise and high-yielding chemical transformations under mild conditions.

OTAVA, in collaboration with Melius Organics, introduces a comprehensive SuFEx Handle Fragment Library, a diverse collection of aryl fluorosulfates and sulfamoyl fluorides designed to expand the druggable proteome, enhance covalent drug development, and facilitate advanced chemical synthesis.

Read more...
 
Inhibitors
inhib.jpgOTAVAchemicals offers a number of INHIBITORS and other biologically active compounds modulating activity of distinct macromolecular targets

 
CHEMriya: Expanding Your Drug Discovery Horizons with 55 Billion Molecules

CHEMriya™ is an ultra-large combinatorial Chemical Space developed by OTAVA to transform hit expansion, hit-to-lead optimization, and compound evolution. Designed to accelerate drug discovery, CHEMriya provides access to a vast collection of chemically diverse molecules for pharmaceutical research and computational screening.
 

Explore CHEMriya on BioSolveIT

Read more...
 
OTAVA tTG2 Inhibitor Library

OTAVA tTG2 Inhibitor Library

Tissue transglutaminase 2 (tTG2) is a multifunctional enzyme involved in extracellular matrix stabilization, cell adhesion, signal transduction, and protein crosslinking. It plays a pivotal role in various physiological processes, but its dysregulation has been implicated in multiple diseases, including celiac disease, fibrosis, cancer, and neurodegenerative disorders. Due to its involvement in disease progression, tTG2 is a prime target for drug discovery, yet the development of small-molecule inhibitors remains an underexplored frontier.

Read more...
 
«StartPrev12345678910NextEnd»

Page 3 of 15
SSL